pen-866
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 29, 2017 (NCT03221400)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 1/Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
Mechanism of action
- EndoplasminINHIBITOR
HSP90B1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1c2c(nc3ccc(OC(=O)N4CCC(CCn5ccc6cc(-n7c(-c8cc(C(C)C)c(O)cc8O)n[nH]c7=O)ccc65)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC- Mol. weight
- 879.97 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297475 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04890093 | Phase 1/Phase 2 (Phase 2) | Dec 7, 2021 | National Cancer Institute (NCI) |
| NCT03221400 | Phase 1/Phase 2 (Phase 2) | Aug 29, 2017 | National Cancer Institute (NCI), Tarveda Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2017 |
| Tarveda Therapeutics | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1